First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Stephen V. Liu, Aaron S. Mansfield et al.|New England Journal of Medicine|2018Cited by 3.5k
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiLMartin Reck, Christian Manegold, Joachim von Pawel et al.|Journal of Clinical Oncology|2009Cited by 1.5k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)Stephen V. Liu, Leora Horn, Javier de Castro et al.|Journal of Clinical Oncology|2021Cited by 818
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Martin Reck, C. Manegold, Joachim von Pawel et al.|Annals of Oncology|2010Cited by 644
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung CancerGiorgio V. Scagliotti, Nasser H. Hanna, Silvia Novello et al.|Journal of Clinical Oncology|2010Cited by 454